Analyst Update: GoPro, Inc., Isis Pharmaceuticals, Inc., and Yandex N.V.

Analysts adjusted their ratings on GoPro Inc (GPRO), ISIS Pharmaceuticals, Inc. (ISIS), and Yandex NV (YNDX)

by Griffin Kruse

Published on Feb 4, 2015 at 11:39 AM
Updated on Apr 20, 2015 at 5:32 PM

Analysts are weighing in today on portable camera maker GoPro Inc (NASDAQ:GPRO), drugmaker ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), and Russian search specialist Yandex NV (NASDAQ:YNDX). Here's a quick look at today's brokerage notes on GPRO, ISIS, and YNDX.

  • GPRO is down 5.2% today to trade at $51.73, after Citigroup slashed its target price to $59 from $94 while reiterating its "neutral" stance on the stock. What's more, GoPro Inc has shed about 18.2% year-to-date, recently hit by Apple Inc.'s (NASDAQ:AAPL) new action-camera patent, and will release earnings after the close tomorrow. Unsurprisingly, short sellers have flocked to the equity, with nearly 29% of GPRO's float sold short (about 14.3 million shares). Also, two-thirds of covering analysts rate the stock a "hold" or worse, and GPRO's consensus 12-month price target of $79.73 stands at a 54.1% premium to current trading levels.

  • Shares of ISIS have lost about 4.7% around midday to hit $61.67, following yesterday's announcement that the company's experimental type 2 diabetes drug doesn't perform as quickly as anticipated. In response, Piper Jaffray cut its price target to $68 from $81, and downgraded the stock to "neutral" from "overweight." Elsewhere, bearish sentiment in ISIS Pharmaceuticals, Inc.'s options pits is nearing a pessimistic peak. Specifically, ISIS' 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.76 sits just 9 percentage points from an annual high.

  • YNDX is up about 0.4% in intraday trading at $15.69, even after Renaissance Capital lowered its price target to $19.20 from $33.80 while underscoring a "buy" rating. On the charts, the stock has been a technical laggard, losing 57.2% year-over-year. However, sentiment in the options pits is bullish, with Yandex NV's 10-day ISE/CBOE/PHLX call/put volume ratio of 14.93 sitting higher than 95% of all other readings taken over the last year. The brokerage bunch is optimistic as well, with all eight covering analysts doling out a "buy" or better rating on the stock.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.
Stocks Surge During Holiday-Shortened Week
Stocks chugged higher as the government responded to the coronavirus crisis with more funding
Bank Stocks Ease Investors Back Into Earnings Season
Bank stocks will kick off earnings season next week
The Top Lithium Play of 2020
Click to continue to advertiser's site.